AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers
02 Junho 2023 - 1:43PM
Dow Jones News
By Michael Susin
AstraZeneca said late Friday that interim analysis of the phase
III study regarding its Imfinzi drug together with chemotherapy
significantly improved pathologic complete response in gastric and
gastroesophageal junction cancers.
The Anglo-Swedish pharma giant said that the trial demonstrated
a statistically significant and clinically meaningful improvement
in the key secondary endpoint of pathologic complete response in
patients with resectable, early-stage and locally advanced gastric
and gastroesophageal junction cancers.
The company said that the trial will continue as planned to
assess overall survival data.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
June 02, 2023 12:28 ET (16:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024